HCW Biologics Inc HCWB

US Biotechnology

$0.98 ▲ +2.97% (+$0.03)

🎈 Low Float 🎢 High Beta 📅 Earnings This Week

Open $0.97

Prev Close $0.95

Day Range $0.96 – $1.00

52W Range $0.95 – $23.94

Market Cap $2.13M

Beta 2.40

EPS (TTM) $-10.91

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2021-07-20
Shares Out.	2,240,000
Website	hcwbiologics.com/ ↗
Phone	18009279800
Employees	35
Revenue	$135,568
Gross Profit	-$93,887
Net Income	-$5.2M
Free Cash Flow	-$12.1M
Total Assets	$26.8M
Total Liabilities	$19.3M
Equity	$7.4M

About HCW Biologics Inc

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

HCW Biologics Inc is a publicly traded company under the ticker symbol HCWB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.